Market Conditions
The biotech market continues to recover, supported by stronger public market performance and improving financing activity. The XBI has materially outperformed the broader S&P 500, while recent IPOs show renewed investor appetite for high quality clinical stage assets
Capital Formation
Healthcare venture investment reached approximately $31 billion across 1,101 deals in the first half of 2026, with Q2 representing the strongest quarter in the dataset. Capital remains concentrated around later stage and clinically validated programs, reflecting continued selectivity toward early scientific risk.
Strategic Activity
M&A activity remains active, particularly in the $500 million to $3 billion range, with a broader group of mid sized and specialty biopharma companies emerging as buyers. This expanding buyer universe is helping support valuations for differentiated clinical stage assets.